Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Glaxosmithkline shares surge 5.63%, among top gainers on Nifty Midcap 150

    In conclusion, GlaxoSmithKline's shares showed significant gains today, reflecting positive market sentiment and strong financial performance.
    Alpha Desk
    August 13, 2025 / 10:36 IST
    Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

    GlaxoSmithKline shares jumped 5.63% to Rs 2,734.50 in Wednesday's trading session, emerging as one of the top gainers on the Nifty Midcap 150 index. The stock's performance reflects positive investor sentiment in today's session.

    Other top gainers on the Nifty Midcap 150 included GE Vernova TD, One 97 Paytm, BSE Limited, and FSN E-Co Nykaa.

    Financial Performance

    Here's a look at the consolidated quarterly and yearly financial performance of GlaxoSmithKline:

    Consolidated Quarterly Financials

    HeadingJun 2024Sep 2024Dec 2024Mar 2025Jun 2025
    RevenueRs 814.65 CroreRs 1,010.77 CroreRs 949.42 CroreRs 974.37 CroreRs 805.17 Crore
    Net ProfitRs 182.33 CroreRs 252.50 CroreRs 229.88 CroreRs 262.87 CroreRs 205.01 Crore
    EPS10.7614.9113.5715.5212.10

    The revenue for the quarter-ending June 2025 was Rs 805.17 Crore, while in the previous quarter-ending March 2025, the revenue was Rs 974.37 Crore. The net profit for the quarter-ending June 2025 stood at Rs 205.01 Crore, compared to Rs 262.87 Crore in the quarter-ending March 2025.

    Consolidated Yearly Financials

    Heading20212022202320242025
    RevenueRs 2,925.60 CroreRs 3,278.03 CroreRs 3,251.72 CroreRs 3,453.71 CroreRs 3,749.21 Crore
    Net ProfitRs 287.27 CroreRs 380.77 CroreRs 607.64 CroreRs 589.96 CroreRs 927.58 Crore
    EPS31.3599.2936.0841.1454.52
    BVPS87.26157.19102.79104.93115.19
    ROE24.2263.6435.4133.4247.67
    Debt to Equity0.000.000.000.000.00

    The company's revenue for the year-ending 2025 increased to Rs 3,749.21 Crore, compared to Rs 3,453.71 Crore in the year-ending 2024. The net profit for the year-ending 2025 stood at Rs 927.58 Crore, compared to Rs 589.96 Crore in the year-ending 2024.

    Consolidated Yearly Income Statement

    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    SalesRs 3,749 CroreRs 3,453 CroreRs 3,251 CroreRs 3,278 CroreRs 2,925 Crore
    Other IncomeRs 145 CroreRs 122 CroreRs 100 CroreRs 75 CroreRs 110 Crore
    Total IncomeRs 3,895 CroreRs 3,576 CroreRs 3,352 CroreRs 3,353 CroreRs 3,036 Crore
    Total ExpenditureRs 2,633 CroreRs 2,758 CroreRs 2,514 CroreRs 2,572 CroreRs 2,578 Crore
    EBITRs 1,261 CroreRs 817 CroreRs 838 CroreRs 781 CroreRs 457 Crore
    InterestRs 1 CroreRs 1 CroreRs 1 CroreRs 2 CroreRs 3 Crore
    TaxRs 332 CroreRs 226 CroreRs 228 CroreRs 398 CroreRs 166 Crore
    Net ProfitRs 927 CroreRs 589 CroreRs 607 CroreRs 380 CroreRs 287 Crore

    Consolidated Quarterly Income Statement

    Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    SalesRs 805 CroreRs 974 CroreRs 949 CroreRs 1,010 CroreRs 814 Crore
    Other IncomeRs 43 CroreRs 40 CroreRs 35 CroreRs 34 CroreRs 35 Crore
    Total IncomeRs 848 CroreRs 1,015 CroreRs 984 CroreRs 1,045 CroreRs 850 Crore
    Total ExpenditureRs 569 CroreRs 655 CroreRs 676 CroreRs 701 CroreRs 600 Crore
    EBITRs 279 CroreRs 359 CroreRs 308 CroreRs 344 CroreRs 249 Crore
    InterestRs 0 CroreRs 0 CroreRs 0 CroreRs 0 CroreRs 0 Crore
    TaxRs 73 CroreRs 95 CroreRs 78 CroreRs 91 CroreRs 67 Crore
    Net ProfitRs 205 CroreRs 262 CroreRs 229 CroreRs 252 CroreRs 182 Crore

    Consolidated Balance Sheet

    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Share CapitalRs 169 CroreRs 169 CroreRs 169 CroreRs 169 CroreRs 169 Crore
    Reserves & SurplusRs 1,781 CroreRs 1,617 CroreRs 1,573 CroreRs 2,493 CroreRs 1,308 Crore
    Current LiabilitiesRs 1,905 CroreRs 1,524 CroreRs 1,326 CroreRs 1,698 CroreRs 1,354 Crore
    Other LiabilitiesRs 251 CroreRs 245 CroreRs 257 CroreRs 271 CroreRs 281 Crore
    Total LiabilitiesRs 4,108 CroreRs 3,556 CroreRs 3,326 CroreRs 4,633 CroreRs 3,114 Crore
    Fixed AssetsRs 297 CroreRs 335 CroreRs 350 CroreRs 361 CroreRs 400 Crore
    Current AssetsRs 3,409 CroreRs 2,798 CroreRs 2,494 CroreRs 3,708 CroreRs 2,202 Crore
    Other AssetsRs 400 CroreRs 423 CroreRs 482 CroreRs 564 CroreRs 511 Crore
    Total AssetsRs 4,108 CroreRs 3,556 CroreRs 3,326 CroreRs 4,633 CroreRs 3,114 Crore
    Contingent LiabilitiesRs 490 CroreRs 387 CroreRs 361 CroreRs 368 CroreRs 498 Crore

    Consolidated Cashflow

    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Operating ActivitiesRs 1,289 CroreRs 582 CroreRs 484 CroreRs 810 CroreRs 577 Crore
    Investing ActivitiesRs -45 CroreRs 8 CroreRs 807 CroreRs -405 CroreRs 418 Crore
    Financing ActivitiesRs -769 CroreRs -561 CroreRs -1,543 CroreRs -524 CroreRs -696 Crore
    OthersRs 0 CroreRs 0 CroreRs 0 CroreRs 0 CroreRs 0 Crore
    Net Cash FlowRs 474 CroreRs 29 CroreRs -251 CroreRs -119 CroreRs 300 Crore

    Consolidated Ratios

    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Basic EPS (Rs.)54.5241.1436.0899.2931.35
    Diluted Eps (Rs.)54.7634.8336.05100.0421.14
    Book Value [Excl. Reval Reserve]/Share (Rs.)115.19104.93102.79157.1987.26
    Dividend/Share (Rs.)54.0032.0032.0090.0030.00
    Face Value1010101010
    Gross Profit Margin (%)35.2929.8627.8225.5524.22
    Operating Margin (%)33.5127.8425.8023.4721.53
    Net Profit Margin (%)24.7417.0818.7851.6912.24
    Return on Networth / Equity (%)47.6733.4235.4163.6424.22
    ROCE (%)57.0347.3341.9526.2135.80
    Return On Assets (%)22.6416.7018.5336.5711.49
    Current Ratio (X)1.791.841.882.181.63
    Quick Ratio (X)1.541.491.531.871.22
    Debt to Equity (x)0.000.000.000.000.00
    Interest Coverage Ratios (X)1,007.30573.35499.36419.65200.69
    Asset Turnover Ratio (%)0.981.000.810.830.94
    Inventory Turnover Ratio (X)0.991.110.811.040.90
    3 Yr CAGR Sales (%)6.958.650.422.370.94
    3 Yr CAGR Net Profit (%)56.0843.31155.34-7.54-9.50
    P/E (x)52.8347.3236.7216.7945.96
    P/B (x)24.9818.5212.8810.5816.51
    EV/EBITDA (x)35.7730.8923.5130.6732.80
    P/S (x)13.009.536.908.598.34

    Corporate Actions

    GlaxoSmithKline has announced several corporate actions, including dividend payouts and bonus issues. Recent announcements include:

    • Analyst/Investor Meet Outcome: An announcement under Regulation 30 (LODR) regarding the outcome of an analyst/investor meet was made on August 8, 2025.
    • Disclosure Under Regulation 30: A disclosure under Regulation 30 was announced on August 5, 2025.
    • Rumour Verification: GlaxoSmithKline Pharmaceuticals Limited informed the Exchange about rumour verification under Regulation 30(11) on August 4, 2025.

    The company has a history of dividend payouts, with the most recent final dividend of Rs.42.00 per share (420%) announced on May 13, 2025, and effective from May 30, 2025. Other dividends include:

    • Interim Dividend: Rs.12.00 per share (120%) announced on October 24, 2024, effective from November 7, 2024.
    • Final Dividend: Rs.32.00 per share (320%) announced on May 17, 2024, effective from May 31, 2024.

    GlaxoSmithKline has also issued bonus shares in the past. Notable bonus issues include:

    • Bonus Ratio 1:1: Announced on July 24, 2018, with an ex-bonus date of September 11, 2018.
    • Bonus Ratio 1:1: Announced on September 28, 1994, with an ex-bonus date of January 2, 1995.

    Additionally, the company had a rights issue:

    • Rights Ratio 1:5: Announced on September 30, 1993, with an ex-rights date of May 21, 1993.

    In conclusion, GlaxoSmithKline's shares showed significant gains today, reflecting positive market sentiment and strong financial performance.

    Alpha Desk

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347